The Clinical Effect of Plasma Exchange in ABO Incompatible Relatives in vivo Kidney Transplantation

doi:10.3969/j.issn.1671-2587.2021.02.007

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2021, Vol. 23 ›› Issue (2): 167-172.DOI: 10.3969/j.issn.1671-2587.2021.02.007

Previous Articles Next Articles

The Clinical Effect of Plasma Exchange in ABO Incompatible Relatives in vivo Kidney Transplantation

ZHANG Yuan-yuan, YING Mei-ai, PAN Jian, et al

0Department of Blood Transfusion,the First Affiliated Hospital of University of Science and Technology of China,Hefei 230022

Received:2020-09-14 Online:2021-04-20 Published:2021-04-19

Abstract

Abstract: Objective To observe the clinical effect of plasma exchange in removing blood group antibody in ABO incompatible relatives kidney transplantation. Methods The clinical characteristics of 54 cases of ABO non-identical relatives kidney transplantation in our hospital from July 2017 to January 2019 were analyzed retrospectively, and the changes of blood group antibody titer after plasma exchange treatment were analyzed. Results The titers of blood group antibodies (including IgG and IgM) were successfully reduced to the preoperative target titer in 2/54 patients, and renal transplantation was successfully carried out in 1/52 patients; One patient had the rebound titer of blood group antibody after operation, and the transplanted kidney failed. Two patients did not reduce the titer of blood group antibody to the target level. They gave up the kidney transplantation and continued the hemodialysis replacement treatment. There were 49 mild adverse events in 128 plasma exchange procedures. Conclusion Plasma exchange is an effective method to reduce the blood group antibody (including IgG and IgM) titer of recipients, which can be used in combination with other immunosuppressants to shorten the pre-operation time of patients with high blood group antibody titer.

Key words: ABO incompatible kidney transplantation, Plasma exchange, Antibody titer

CLC Number:

R692.5R457.2

ZHANG Yuan-yuan, YING Mei-ai, PAN Jian, et al. The Clinical Effect of Plasma Exchange in ABO Incompatible Relatives in vivo Kidney Transplantation[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 167-172.

References

[1] ROODNAT J I,KAL-VAN GESTEL J A,ZUIDEMA W,et al.Successful expansion of the living donor pool by alternative living donation programs[J].Am J Transplant,2009,9(9):2150-2156.
[2] TANABE K, TAKAHASHI K, SONDA K, et al.Long-term results of ABO-incompatible living kidney transplantation: a single-center experience[J].Transplantation,1998,65(2):224-228.
[3] ZSCHIEDRICH S,KRAMER-ZUCKER A,JÄNIGEN B,et al.An update on ABO-incompatible kidney transplantation[J].Transpl Int,2015,28(4):387-397.
[4] 王毅. ABO血型不相容亲属活体肾移植临床诊疗指南(2017版)[J].中华移植杂志(电子版),2017,11(4):193-200.
[5] 戚贵生,李佳蔚,蒋密,等.ABO血型不相容(ABOi)的亲属肾移植受体个体化预处理的探索[J].复旦学报(医学版),2020,47(1): 31-36
[6] 邱江,陈国栋,阮和欢,等.ABO血型不相容亲属活体肾移植的脱敏治疗[J].中华器官移植杂志,2019,40(8):478-483.
[7] 王显丁,邱阳,吕远航,等.ABO血型不相容亲属活体肾移植的临床分析[J].中华器官移植杂志,2018,39(1):29-34.
[8] HATAKEYAMA S,FUJITA T,MURAKAMI R,et al.Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation:a single-center experience[J].Transplant Proc,2014,46(2):445-448.
[9] MURAMATSU M,GONZALEZ H D,CACCIOLA R,et al.ABO incompatible renal transplants:Good or bad?[J].World J Transplant,2014,4(1):18-29.
[10] TOBIAN A A,SHIREY R S,MONTGOMERY R A,et al.ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation[J].Am J Transplant,2010,10(5):1247-1253.
[11] BÖHMIG G A,FARKAS A M,ESKANDARY F,et al.Strategies to overcome the ABO barrier in kidney transplantation[J].Nat Rev Nephrol,2015,11(12):732-747.
[12] 雷文华,刘帅辉,周静怡,等.不同免疫诱导方案对ABO血型不相容亲属活体肾移植受者临床结局的影响[J].中华器官移植杂志,2019,40(2):78-82.
[13] OKUMI M,KAKUTA Y,UNAGAMI K,et al.Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience[J].Transl Androl Urol,2019,8(2):126-133.
[14] ISHIDA H,MIYAMOTO N,SHIRAKAWA H,et al.Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation——single center analysis[J].Am J Transplant,2007,7(4): 825-831.
[15] GENBERG H,KUMLIEN G,WENNBERG L,et al.The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation[J].Nephrol Dial Transplant,2011,26(7):2394-2400.
[16] TANABE K.Double-filtration plasmapheresis[J].Transplantation,2007,84(12 suppl):S30-S32.
[17] PARMENTIER S P,ROSENKRANZ E, SCHIRUTSCH-KE H,et al.Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible ki-
dney transplant recipients[J].Atheroscler Suppl, 2017, 30:253-256.
[18] TAKAHASHI K,SAITO K,TAKAHARA S,et al.Re-sults of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation[J].Clin Exp Nephrol,2017,21(4):705-713.
[19] FLINT S M,WALKER R G,HOGAN C,et al.Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression[J].Am J Transplant,2011,11(5):1016-1024.
[20] JHA P K,TIWARI A K,BANSAL S B,et al.Cascade plasmapheresis as preconditioning regimen for ABO-incompatible renal transplantation:a single-center experience[J].Transfusion,2016,56(4):956-961.

The Clinical Effect of Plasma Exchange in ABO Incompatible Relatives in vivo Kidney Transplantation

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	CHEN Fu-qiang, ZHU Hai-feng, XIAO Chen, et al. Analysis on Results of Different Reagent Kits of IgM and IgG in COVID-19 Convalescent Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(3): 258-263.
[2]	HU Xiao-yu, WU Xue-zhong, CHENG Wei-fang, et al. Syphilis Confirmatory Testing and Syphilis Infection Status Analysis of the Blood Donors on the Unqualified Results of Anti-TP Antibody Screening [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(2): 142-147.
[3]	CAO Xin-rui, MA Xiao-nan, YU Xiao-nan. Therapeutic Effect of Plasma Exchange on the Auxiliary Treatment of Exertional Heat Stroke with Early Severe Hepatic Lesions [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(1): 42-44.
[4]	CHEN Yang, CUI Ying, MENG Jun-ping, etal. An Analysis of Plasma Exchange Therapy in Patients with Crescent Type Glomerulonephritis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(5): 505-507.
[5]	LI Wen-hua，YUAN Gao-jie，YE Yin，et al.. The Treatment Measures and Clinical Application of Plasma Exchange at Bedside [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(3): 231-234.
[6]	TAN Fang，LUO Juan，TENG Ben-xiu，et al.. Efficacy of Therapeutic Plasma Exchange in Treatment of Acute Hyperlipidemic Pancreatitis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(3): 235-237.
[7]	ZHANG Yuan-yuan，YING Mei-ai，PAN Jian，et al.. A Comparison of Plasma Exchange Performance between Two Blood Cell Separators [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(3): 238-241.
[8]	YANG Peng，WEN Hui-qin，WEI Yu-zhi，et al.. The Safety of Therapeutic Plasmapheresis in Patients with Critical Diseases [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(3): 242-245.